SGLT-2 inhibitors are associated with a substantial reduction in the risk of heart failure hospitalization (odds ratio [OR] 0.70, 95% CI 0.63–0.77), while GLP-1 analogues demonstrate minimal to no impact in this regard (OR 0.94, CI 0.85–1.03). The gene discussed is GCG; the disease is heart failure.